Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldara mechanism in actinic keratosis
NCT00335179Phase 2Completed
- Sponsor
- Graceway Pharmaceuticals
- Start
- Jan 2003
- Primary completion
- Jul 2003
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in actinic keratosis (AK) comparing Imiquimod cream with Vehicle cream (2 arms). Primary endpoint: Gene expression profiling of treated lesions at 8 weeks. Started Jan 2003; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00335179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335179.